Skip to main content
ANIK logo

Anika Therapeutics, Inc.

ANIKNASDAQHealthcareDrug Manufacturers - Specialty & Generic

$21.27Today:- (-)1Y +118.55%

As of Oct 26, 2026 close

Market cap
$291.76M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$9.01$22.88
Volume (live)
-
Avg. volume (3M)
99.98K

Anika Therapeutics (ANIK) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Anika Therapeutics generated $11.19M of operating cash flow and spent $6.83M on capital expenditures. That left free cash flow of $4.36M, or 3.9% of revenue. It repurchased $11.05M of its own shares.

Anika Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Anika Therapeutics, Inc. (ANIK) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-10.88-56.39-82.67-14.864.13-23.9827.1918.7231.82
Depreciation & Amortization5.738.1214.2214.4914.3213.465.995.914.29
Deferred Income Tax-0.010.26-6.33-5.27-1.77-3.540.79-1.82-1.20
Stock Based Compensation10.0813.1315.2414.3211.095.396.0911.055.81
Change in Working Capital-0.82-13.09-12.12-11.82-14.72-13.46-6.64-3.20-2.36
Change in Accounts Receivable0.413.37-1.31-5.63-6.225.86-1.842.912.67
Change in Inventory0.03-9.42-11.40-6.87-6.62-14.18-5.59-7.58-6.52
Change in Accounts Payable0.04-2.51-0.011.97-1.100.820.77-1.673.89
Change in Other Working Capital0.33-4.532.23-1.28-12.94-3.890.013.13-2.40
Other Operating Activities7.0853.372.237.56-12.94-14.123.584.262.45
Net Cash from Operating Activities11.195.40-1.794.418.4013.0737.0134.9240.81
Investing Activities
Capital Expenditures-6.83-7.73-5.43-7.49-5.14-1.63-2.83-4.66-8.98
Acquisitions8.990.000.000.00-0.48-94.60-42.520.000.00
Purchases of Investments0.000.000.000.000.0024.97-103.85-91.60-45.00
Sales/Maturities of Investments0.000.000.000.002.5045.00146.3746.0041.50
Other Investing Activities1.33-0.600.000.000.000.0042.52-45.60-3.50
Net Cash from Investing Activities-0.40-8.33-5.43-7.49-3.12-71.2639.69-50.26-12.48
Financing Activities
Debt Repayment0.000.000.00-0.28-0.20-0.560.000.000.00
Common Stock Issued0.500.000.000.000.001.520.000.000.31
Common Stock Repurchased-11.05-10.91-5.000.000.00-0.26-30.00-30.000.00
Other Financing Activities-1.57-1.82-2.15-4.57-7.71-4.4821.861.100.31
Net Cash from Financing Activities-10.55-12.73-6.32-4.85-6.78-3.77-8.14-28.900.31
Summary
Effect of Forex Changes on Cash0.09-0.050.08-0.130.070.33-0.130.030.35
Net Change in Cash0.32-15.71-13.46-8.06-1.50-61.6568.42-44.2129.00
Cash at Beginning of Period57.1672.8786.3394.3995.82157.4689.04133.26104.26
Cash at End of Period57.4857.1672.8786.3394.3995.82157.4689.04133.26
Free Cash Flow4.36-2.33-7.22-3.083.2511.4434.1830.2631.83
Supplemental Disclosures
Income Taxes Paid-3.993.120.111.230.99---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Anika Therapeutics Cash Flow

What is Anika Therapeutics's free cash flow?

Anika Therapeutics generated free cash flow of $4.36M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of $11.19M minus $6.83M of capital expenditures. Free cash flow equaled 3.9% of revenue.

How much does Anika Therapeutics spend on capital expenditures?

Anika Therapeutics spent $6.83M on capital expenditures in fiscal 2025, compared with $7.73M a year earlier. That equals 61.0% of operating cash flow.

Does Anika Therapeutics pay dividends or buy back shares?

Yes. In fiscal 2025 Anika Therapeutics returned $11.05M in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition